Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Advanced Solid Tumor × BID protein, human × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Prostatic Neoplasms 1 Neoplasms by Histologic Type 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Myeloproliferative Disorders 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia 1 Hematologic Diseases 1 Granulosa Cell Tumor 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Bone Marrow Diseases 1 Advanced Solid Tumor 1

Interventions

Injections 3 atezolizumab 2 Leucovorin 2 Irinotecan 2 ulixertinib 1 toripalimab 1 tipifarnib 1 pembrolizumab 1 olaparib 1 mirdametinib 1 famitinib 1 camrelizumab 1 Ramucirumab 1 Radiation 1 Paclitaxel 1 IFL protocol 1 Granulocyte Colony-Stimulating Factor 1 Gemcitabine 1 Fluorouracil 1 Docetaxel 1 Bevacizumab 1 BID protein, human 1 Appointments and Schedules 1 Albumin-Bound Paclitaxel 1 APG-1387 1 5-fluorouridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06560632 2026-01-16

POLAR

Repare Therapeutics

Phase 1 Terminated

26 enrolled 14 charts

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡